Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30323683 | 0.82 | CMA1 (0.47) | IDO1AGXTCMA1TAAR1MMP13 | |
| SCHEMBL4237467 | 0.82 | CMA1 (0.47) | IDO1AGXTCMA1TAAR1MMP13 | |
| SCHEMBL4248141 | 0.81 | IDO1 (0.54) | IDO1AGXTMAOBCMA1TAAR1 | |
| SCHEMBL4150229 | 0.80 | TSHR (0.48) | — | |
| SCHEMBL12093572 | 0.80 | IDO1 (0.65) | IDO1AGXTMAOBCMA1TAAR1 | |
| SCHEMBL29648388 | 0.78 | TSHR (0.51) | IDO1AGXTMAOBTAAR1MMP13 | |
| SCHEMBL3768643 | 0.78 | IDO1 (0.71) | IDO1AGXTMAOBCMA1TAAR1 | |
| SCHEMBL21875855 | 0.77 | IDO1 (0.61) | IDO1AGXTMAOBCMA1TAAR1 | |
| SCHEMBL4802894 | 0.75 | ALDH1A1 (0.38) | — | |
| SCHEMBL6205291 | 0.75 | IDO1 (0.62) | IDO1AGXTMAOBCMA1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371739-B2 | Aryl fructose-1,6-bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | IDO1 697/4885AGXT 150/4885MAOB 977/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | IDO1 930/4885AGXT 123/4885MAOB 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.